AbbVie Advances Rinvoq Toward Vitiligo Treatment Approval

Pharmaceutical company AbbVie has filed applications with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of its JAK inhibitor Rinvoq into a new therapeutic area: the treatment of adult and adolescent patients suffering from non-segmental vitiligo. This skin condition, which causes depigmentation and loss of skin color, affects millions of patients worldwide seeking effective therapeutic solutions. The regulatory submissions mark a significant step toward providing patients with an additional treatment option for this challenging dermatological condition.

Robust Phase 3 Clinical Trial Outcomes

The applications are anchored in compelling data from the Phase 3 Viti-Up studies, which demonstrated that upadacitinib—the active ingredient in Rinvoq—successfully met its co-primary efficacy endpoints. Specifically, the trial showed that at least 50% of patients achieved meaningful improvements in total body repigmentation by week 48, while more than 75% of participants experienced significant facial repigmentation improvements over the same period. These clinical results underscore the potential of JAK inhibition as a mechanism for restoring skin pigmentation in vitiligo patients, offering hope for individuals who have historically faced limited therapeutic options.

Expanding Rinvoq’s Therapeutic Portfolio

Beyond the vitiligo indication, Rinvoq has already established a strong clinical presence in managing various immune-mediated inflammatory diseases. The prescription medication is currently authorized for treating rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, among other inflammatory conditions. This regulatory expansion into vitiligo treatment reflects the growing recognition of JAK inhibitors’ versatility in modulating immune dysfunction across multiple disease states. Successfully gaining approval for vitiligo would further solidify Rinvoq’s position as a key therapeutic agent in AbbVie’s dermatology and immunology portfolios.